1 Nutrition and Dietetic Service, Hospital de Câncer I, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, Brazil.
2 Bone Marrow Transplantation Laboratory, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, Brazil.
Nutr Clin Pract. 2017 Feb;32(1):122-129. doi: 10.1177/0884533616653807. Epub 2016 Jul 9.
This study evaluated the effect of an immune-modulatory diet on patients with gastric cancer and identified the parameters associated with postoperative outcomes. This was a single-arm prospective intervention study. At baseline, patients were assessed for nutrition (Patient-Generated Subjective Global Assessment), inflammatory markers (albumin, C-reactive protein, and interleukin 6 [IL-6]), and immune markers (percentage NK, CD4, CD8, and CD4:CD8 ratio); they also received nutrition counseling and high-calorie/protein supplement. A week before surgery, they were assessed for nutrition and inflammatory/immune markers and started on an immune-modulatory supplement until the day before surgery, when they were evaluated again. On the second postoperative day, patients were assessed for inflammatory/immune parameters, and a final nutrition evaluation was performed until the day of discharge. Complications were recorded daily and up to 30 days after discharge. Thirty-seven patients (60 ± 10 years old) were included, and 57% were classified as malnourished. Maintenance of nutrition and immune parameters occurred throughout the study period, but we found a preoperative increase in C-reactive protein (0.1-1.5 mg/dL) and IL-6 (2.0-14.2 pg/mL) and a postoperative increase in the CD4:CD8 ratio (2.3 ± 1.0). Complications and death were seen in 35%, especially patients with higher preoperative IL-6 (2.2-46 pg/mL), lower CD4:CD8 ratio (1.7 ± 0.5), and lower protein (1.2 ± 0.5 g/kg/d) and calorie intake (1552 ± 584 kcal/kg/d). The high-calorie/protein supplementation with the immune-modulating diet was able to maintain the nutrition and immune status of patients with gastric cancer.
这项研究评估了免疫调节饮食对胃癌患者的影响,并确定了与术后结果相关的参数。这是一项单臂前瞻性干预研究。在基线时,评估患者的营养状况(患者主观整体评估)、炎症标志物(白蛋白、C 反应蛋白和白细胞介素 6 [IL-6])和免疫标志物(NK 百分比、CD4、CD8 和 CD4:CD8 比值);他们还接受了营养咨询和高卡路里/蛋白质补充。手术前一周,评估他们的营养和炎症/免疫标志物,并开始使用免疫调节补充剂,直到手术前一天再次评估。术后第二天,评估患者的炎症/免疫参数,并进行最后一次营养评估,直到出院日。每天记录并发症,并在出院后 30 天内进行。共纳入 37 名患者(60 ± 10 岁),其中 57%被归类为营养不良。在整个研究期间,营养和免疫参数得以维持,但我们发现术前 C 反应蛋白(0.1-1.5 mg/dL)和白细胞介素 6(2.0-14.2 pg/mL)增加,术后 CD4:CD8 比值(2.3 ± 1.0)增加。35%的患者出现并发症和死亡,特别是术前白细胞介素 6 较高(2.2-46 pg/mL)、CD4:CD8 比值较低(1.7 ± 0.5)、蛋白质(1.2 ± 0.5 g/kg/d)和热量摄入(1552 ± 584 kcal/kg/d)较低的患者。高卡路里/蛋白质补充与免疫调节饮食相结合,能够维持胃癌患者的营养和免疫状态。